Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D5WU7B
|
|||
| Drug Name |
CEND-1
|
|||
| Synonyms |
iRGD; UNII-Z8MXU5GH4Q; Z8MXU5GH4Q; iRGD-peptide; 1392278-76-0; Internalized-arginylglycylaspartic acid cyclic peptide; Q48988348; L-Cysteine, L-cysteinyl-L-arginylglycyl-L-alpha-aspartyl-L-lysylglycyl-L-prolyl-L-alpha-aspartyl-, cyclic (1->9)-disulfide
Click to Show/Hide
|
|||
| Drug Type |
Peptide
|
|||
| Indication | Pancreatic cancer [ICD-11: 2C10; ICD-9: 157] | Phase 1 | [1] | |
| Company |
Cend Therapeutics
|
|||
| Structure |
 |
Download2D MOL
|
||
| Formula |
C35H57N13O14S2
|
|||
| Canonical SMILES |
C1CC2C(=O)NC(C(=O)NC(CSSCC(C(=O)NC(C(=O)NCC(=O)NC(C(=O)NC(C(=O)NCC(=O)N2C1)CCCCN)CC(=O)O)CCCN=C(N)N)N)C(=O)O)CC(=O)O
|
|||
| InChI |
1S/C35H57N13O14S2/c36-8-2-1-5-18-30(57)42-14-25(50)48-10-4-7-23(48)33(60)46-21(12-27(53)54)32(59)47-22(34(61)62)16-64-63-15-17(37)28(55)44-19(6-3-9-40-35(38)39)29(56)41-13-24(49)43-20(11-26(51)52)31(58)45-18/h17-23H,1-16,36-37H2,(H,41,56)(H,42,57)(H,43,49)(H,44,55)(H,45,58)(H,46,60)(H,47,59)(H,51,52)(H,53,54)(H,61,62)(H4,38,39,40)/t17-,18-,19-,20-,21-,22-,23-/m0/s1
|
|||
| InChIKey |
YHTTWXCDIRTOQX-FQJIPJFPSA-N
|
|||
| CAS Number |
CAS 1392278-76-0
|
|||
| PubChem Compound ID | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT03517176) CEND-1 in Combination With Nabpaclitaxel and Gemcitabine in Metastatic Pancreatic Cancer. U.S. National Institutes of Health. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.